A Randomized, 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO(Rm) (15mg BID [twice daily]) in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Randomized, 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO(Rm) (15mg BID [twice daily]) in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Cilomilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2008 Status changed from in progress to completed accordnig to ClinicalTrials.gov.
    • 03 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top